[PDF] Top 20 ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum based chemotherapy

... Overall, patients with LABC - including cases present- ing an inflammatory disease and, mostly, those carrying a triple-negative breast cancer - are particularly respon- sive to DNA-damaging agents ... See full document

... demonstrated patients with low ERCC1 levels had chemosensitive than those with high ERCC1 ...of ERCC1 is correlated with platinum drug resistance in breast cancer ...The ... See full document

... whether ERCC1 rs11615 and rs3212986 and ERCC2 rs13181 and rs1799793 gene polymorphisms could serve as potential biomarkers for the prognosis of gastric can- ...228 patients with pathologically proven ... See full document

... with patients with A/G or G/G ...as ERCC1), and GST families may affect antican- cer drug efficacy for ...in patients with ...genetic polymorphisms in predicting clinical outcomes of GC ... See full document

... Abstract: Platinum-based chemotherapy is the front-line treatment in patients with metastatic non-small cell lung cancer ...of platinum-based chemotherapy induced ... See full document

... strategies based on a better understanding of tumor biology are thus needed to maximize the effi- cacy of current ...to chemotherapy have been investigated, and the selection of effective chemo- therapy ... See full document

... to chemotherapy, a majority of studies focus attention on pCR cases, while detailed analyses of partial responder or non-responder cases are relatively rare ...of breast cancer patients ... See full document

... of markers with ER or other standard parameters does not necessarily imply that those genes could simply be replaced by respective param- ...some markers with Her-2 in pre- dictive signatures supports the ... See full document

... Keywords: breast cancer, lymphocyte-to-monocyte ratio, 5-fluorouracil, prognostic factor Received: December 03, 2015 Accepted: April 11, 2016 Published: April 26, 2016 ABSTRACT Several reports have ... See full document

... AXL-expressing breast cancer cells and TAMs, and its impact on tumor progression and anticancer drug ...and breast cancer cells, we measured the release of several major cytokines/chemokines ... See full document

... in patients with MM treated with gemcitabine-platinum combination ...investigated polymorphisms influ- enced tumor response or ...in platinum-based che- ...in cancer ... See full document

... gastric cancer, there were 51 cases, 31 males and 20 females, wi- th a median age of ...45 patients of intestinal-type gastric cancer con- tained 26 males and 19 females with an aver- age age of ... See full document

... first-line chemotherapy combining bevacizumab with taxanes (13, 14, 16, 18) is that after a maximal response was reached in our study, bevacizumab was continued as a maintenance treatment with endocrine therapy in ... See full document

... nucleotide polymorphisms (SNPs) of genes of these pathways modulate outcomes of patients with advanced non –small cell lung cancer (NSCLC) treated with first-line platinum-based ... See full document

... of patients (approximately 20%) received radiotherapy or target therapy because of tumor progression, but there was no significant difference in the dif- ferent genotypes of the four ...CT polymorphisms ... See full document

... All patients in our study received taxane-based adjuvant ...in cancer, we hypothesize that poly- morphisms in AURKA or AURKB might contribute to taxane resistance and then influence the survival of ... See full document

... of breast cancer [16,26]; however, Ki67 alone is not an independent prognostic factor for TNBC with adjuvant ...TNBC patients treated by the adjuvant chemotherapeutic regimen, only at ... See full document

... ammatory markers and immune-based prognostic indexes were used to evaluate the prognosis of breast cancer, such as NLR, d-NLR, MLR/LMR, and ...ammatory markers were associated ... See full document

... as patients treated with trastuzumab-containing NAC. However, based on results of big clinical trials, such as HERA, BCIRG 006, NCCTG N9831, and NSABP B-31, trastuzumab was approved for adjuvant ... See full document

... in cancer cell nuclei was associated with poor survival [35-37], while only a few studies have reported a reverse correlation ...on breast and lung cancer, have also shown the influence of nuclear ... See full document